College Directory

Holly Hagan,

PhD, MPH, RN
Professor
726 Broadway, 10th Floor
New York, NY 10003
Phone: 
212-998-5221
Fax: 
212-995-3143
Email: 
hh50@nyu.edu
Areas of Specialization 

Epidemiology, infectious diseases, viral hepatitis, HIV, substance abuse, research methods, health disparities, systematic reviews, meta-analyses, implementation science

Education 
PhD, 1997, University of Washington
MPH, 1987, University of Massachusetts, Amherst
RN, 1981, Seattle Central College
BA, 1975, The Evergreen State College
Professional Overview 
Dr. Hagan trained as an epidemiologist at the University of Washington and is expert in the infectious disease consequences of illicit drug use. Her work on the etiology, epidemiology and prevention of HCV in substance users has informed harm reduction practices in the US and abroad. Dr. Hagan served on the Institute of Medicine Committee on the Prevention and Control of Viral Hepatitis in the United States. She is Director of the Transdisciplinary Research Methods Core in the Center for Drug Use and HIV Research within NYU College of Nursing.
Licensure 
Registered Nurse, Washington State (inactive)
Professional Membership 
American Association for the Study of Liver Disease
American Public Health Association
International AIDS Society
International Harm Reduction Association
North American Syringe Exchange Network, Board Member
Society for Epidemiologic Research
Current Research Projects
National Institutes of Health
PhD, MPH, RN, Professor, hh50@nyu.edu

This study will use the methods of Implementation Science - research synthesis, mathematical modeling and simulation, and comparative effectiveness analyses - to determine how best to constitute a portfolio of interventions for the prevention and control of HCV and its consequences while taking into limited resources and underlying epidemiologic and social network features account. A dissemination plan will make extensive use of technology, including social media, and guidance from key stakeholders.

Publications
Des Jarlais, D.C., Arasteh, K., McKnight, C., Perlman, D.C., Cooper, H.L. & Hagan, H. (2013). HSV-2 infection as a cause of female/male and racial/ethnic disparities in HIV infection. PLoS One, 8, e66874. 10.1371/journal.pone.0066874.
Pouget, E.R., Hagan, H., & Des Jarlais, D.C. (2012). Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.. Addiction, 107, 1057-1065. 10.1111/j.1360-0443.2011.03765.x.
Hagan H., Pouget E.R., & Des Jarlais D.C. (2011). A systematic review and meta-analysis of interventions to prevent hepatitis C virus seroconversion in people who inject drugs. Journal of Infectious Diseases, 204, 74-83. 10.1093/infdis/jir196.
Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak,D., & Degenhardt, L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet, 378, 571-583. 10.1016/S0140-6736(11)61097-0.
Hagan, H. (2011). Invited commentary: Agent, host and environment: hepatitis C virus in people who inject drugs . Journal of Infectious Diseases, 204, 1819-1821.
Hagan, H., Pouget, E.R., Williams, I.T., Garfein, R.L., Strathdee, S.A., Hudson, S. M., Latka, M.H., & Ouellet, L.J. (2010). Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. Journal of Infectious Diseases, 201, 378-385. 10.1086/649783.
Hagan, H., Jenness, S.M., Wendel, T., Murrill, C.R., Neaigus, A., Gelpi-Acosta, C. (2010). Herpes simplex virus type 2 associated with HIV infection among New York heterosexuals living in high-risk areas. International Journal of STD & AIDS, 21, 580-583. 10.1258/ijsa.2010.010137.
Hagan, H., Pouget, E.R., Des Jarlais. D.C., & Lelutiu-Weinberger, C. (2008). Meta-regression of hepatitis C virus (HCV) infection in relation to time since onset of illicit drug injection: The influence of time and place. American Journal of Epidemiology, 168, 1099-1109. 10.1093/aje/kwn237.
Hagan, H., Latka, M., Campbell, J.V., Golub, E.T., Garfein, R.S., Thomas, D.A., Kapadia, F., & Strathdee, S.A. (2006). Eligibility for treatment of hepatitis C virus infection among young injection drug users in three US cities. Clinical Infectious Diseases, 42, 669-672. 10.1086/499951.
Hagan, H., Thiede, H., Weiss, N.S., Hopkins, S.G., Duchin, J., & Alexander, E.R. (2001). Sharing of drug preparation equipment associated with hepatitis C virus seroconversion in drug injectors. American Journal of Public Health, 91, 42-46. PMCID: PMC1446500.
Hagan, H., Des Jarlais, D.C., Friedman, S.R., Purchase, D., & Alter, M.J. (1995). Reduced risk of hepatitis B and hepatitis C in injecting drug users participating in the Tacoma syringe exchange program. American Journal of Public Health, 85, 1531-1537. PMCID: PMC1615682.